Full-Time

VP – Market Access

Posted on 11/15/2024

Ceribell

Ceribell

201-500 employees

EEG devices for monitoring brain activity

Healthcare

Compensation Overview

$297k - $335kAnnually

+ Bonus + Equity

Expert

Sunnyvale, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Bachelor's degree in Health Policy, Economics, Engineering, or other analytics-related fields.
  • MBA or equivalent advanced degree preferred
  • Minimum 15 years of relevant experience in market access and disruptive medical devices
  • Previous experience in managing teams in market access
  • Knowledge and prior experience with NTAP
Responsibilities
  • Lead a team of field market access managers that support our sales teams and accounts with implementing reimbursement structures (e.g., NTAP) related to our product
  • Develop relationships with key customer counterparts across revenue cycle, billing / coding, finance, nursing and quality to ensure successful implementation
  • Manage reimbursement support processes for to efficiently support Ceribell’s commercial efforts
  • Lead research into new market segments and reimbursement structures to support our commercialization efforts outside short-term acute care hospitals
  • Develop and execute strategies for new reimbursement structures and codes in adult acute care seizure
  • Build and manage relationships with a set of peer advisors to support account conversations
  • Work with clinical to develop additional health economic evidence to support Ceribell’s product adoption
  • Support efforts with societies and 3rd party advisors to shape new reimbursement and market access opportunities for Ceribell’s platform
  • Support new product introduction efforts with research on reimbursement structures in new market segments and new coding opportunities

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data on a patient's brain activity, which is essential for diagnosing and treating neurological conditions, particularly in urgent situations like Nonconvulsive Status Epilepticus (NCSE). Unlike some other medical devices, the Ceribell EEG Recorder does not provide diagnostic conclusions or automated alerts; instead, it serves as a tool for healthcare professionals to collect data for interpretation. Ceribell differentiates itself by focusing on the speed of data collection, which is critical in time-sensitive medical scenarios. The company's goal is to enhance the ability of healthcare providers to make informed treatment decisions quickly, ultimately improving patient outcomes.

Company Stage

Series C

Total Funding

$146.9M

Headquarters

Mountain View, California

Founded

2014

Growth & Insights
Headcount

6 month growth

11%

1 year growth

25%

2 year growth

63%
Simplify Jobs

Simplify's Take

What believers are saying

  • Ceribell's recent $102 million equity investment and $50 million financing round indicate strong financial backing for expansion and product development.
  • The appointment of experienced leaders like Sean Manni and Joshua Copp positions the company for strategic growth and operational excellence.
  • Recognition by Fast Company as one of the World's Most Innovative Companies highlights Ceribell's industry impact and potential for continued innovation.

What critics are saying

  • The reliance on healthcare providers to interpret EEG data may limit the device's adoption in settings with less specialized staff.
  • The competitive landscape in medical devices and AI-powered diagnostics could pose challenges to Ceribell's market share.

What makes Ceribell unique

  • Ceribell's AI-powered point-of-care EEG system is a first-of-its-kind technology, setting it apart from traditional EEG devices.
  • The company's focus on rapid, easy-to-use brain monitoring solutions for time-critical conditions like NCSE provides a unique value proposition.
  • FDA Breakthrough Device Designation for delirium detection further validates Ceribell's innovative approach in neurodiagnostics.

Help us improve and share your feedback! Did you find this helpful?